Hashimoto Encephalopathy (HE/SREAT): Comprehensive Disease Characterization Report

Summary

Hashimoto Encephalopathy (HE), also known as Steroid-Responsive Encephalopathy Associated with Autoimmune Thyroiditis (SREAT), is a rare, heterogeneous autoimmune encephalopathy defined by the presence of elevated antithyroid antibodies (anti-TPO and/or anti-TG), neuropsychiatric symptoms, and characteristic responsiveness to immunosuppressive therapy. First described by Brain et al. in 1966, HE remains one of the most clinically contested entities in neuroimmunology. Its diagnostic validity is challenged by findings that anti-TPO antibody prevalence in suspected HE patients (~8.1%) is nearly identical to that in healthy controls (~8.2%), and complete steroid response occurs in only ~32% of cases (PMID: 31882532). Despite these controversies, HE represents a clinically important diagnosis of exclusion because it identifies a subset of patients with severe, potentially reversible encephalopathy who respond to immunotherapy.

The clinical presentation is dominated by cognitive impairment (76.9%), seizures (46.1%), psychiatric symptoms including psychosis (38.5%), myoclonus (30.8%), and sleep disturbances (69.2%), occurring predominantly in females (F:M ratio ~4:1) who are typically euthyroid at presentation, with a bimodal age distribution peaking at 20-30 and 50-70 years (PMID: 19363998; PMID: 26167010). The pathophysiology remains incompletely understood, with four competing mechanistic hypotheses (autoimmune vasculitis, anti-neuronal antibodies, T-cell mediated immunity, and blood-brain barrier dysfunction). A landmark 2026 mouse model study identified HMGB1 as a key molecular mediator translating peripheral thyroid autoimmunity into central neuroinflammation via microglial activation and neurotoxic A1 astrocyte polarization (PMID: 41782877). Treatment follows a stepwise immunotherapy algorithm -- IV methylprednisolone as first-line (~61% effectiveness, ~32% relapse), followed by IVIG, plasmapheresis, rituximab, and novel FcRn antagonists for refractory cases -- with the majority of patients achieving at least partial recovery.

This report synthesizes evidence from 105 published papers and 13 confirmed findings across all 15 disease characterization domains, providing ontology-annotated entries suitable for knowledge base population.

1. Disease Information

Overview

Hashimoto Encephalopathy is a rare autoimmune encephalopathy associated with Hashimoto's thyroiditis, characterized by acute or subacute neuropsychiatric symptoms in the context of elevated antithyroid antibodies. The condition was first described in 1966 and has since been recognized as a treatable cause of encephalopathy, though its nosological status remains debated.

Key Identifiers

Synonyms and Alternative Names

• Steroid-Responsive Encephalopathy Associated with Autoimmune Thyroiditis (SREAT)
• Encephalopathy Associated with Autoimmune Thyroid Disease (EAATD)
• Nonvasculitic Autoimmune Inflammatory Meningoencephalitis (NAIM)
• Autoimmune Thyroid-Associated Encephalopathy

Data Sources

Information is derived primarily from aggregated disease-level resources including case series, systematic reviews, and retrospective cohort studies. The largest case series comprises 84 patients from multiple institutions across Japan and other countries (PMID: 19363998). Individual patient data come from case reports, small retrospective cohorts, and a 2024 systematic review analyzing treatment outcomes (PMID: 39000209).

2. Etiology

Disease Causal Factors

The precise etiology of HE remains unknown. The condition is fundamentally autoimmune in nature, arising in the context of Hashimoto's thyroiditis, but the specific mechanism by which thyroid autoimmunity produces central nervous system (CNS) dysfunction is debated. As stated by Manocchio et al. (2025): "While elevated TPO antibodies are frequently observed, a direct causal relationship with HE is unlikely, and their presence may indicate a general state of autoimmunity" (PMID: 40149702).

Genetic Risk Factors

No HE-specific causal genes have been identified. HE shares genetic susceptibility with autoimmune thyroid disease (AITD), which has approximately 70% heritability from twin studies. Key susceptibility genes include:

Lee et al. (2015) summarized: "AITD susceptibility genes can be categorized as either thyroid specific (Tg, TSHR) or immune-modulating (FOXP3, CD25, CD40, CTLA-4, HLA), with HLA-DR3 carrying the highest risk" (PMID: 26235382).

Environmental Risk Factors

• Iodine excess: Regions with higher iodine status show different DNA methylation patterns in AITD genes (ITGA6, PRKAA2, DAPK1) (PMID: 36420742)
• Selenium deficiency: Low selenium levels may increase AITD risk (data inconclusive)
• Vitamin D deficiency: Potential risk factor (data inconclusive) (PMID: 24609834)
• Infections: May trigger disease via molecular mimicry (PMID: 21234711)
• Smoking: Paradoxically diminished risk for Hashimoto's thyroiditis (PMID: 24609834)
• Female sex: Strongest demographic risk factor (F:M ratio 4:1 to 5:1), partially explained by fetal microchimerism and X-chromosome inactivation (PMID: 24609834)

Gene-Environment Interactions

Tomer et al. (2011) established the mechanistic framework: "These genes interact with environmental factors, such as infection, likely through epigenetic mechanisms to trigger disease" (PMID: 21234711). Epigenetic modifications include DNA methylation changes in immunoregulatory genes (TNF, IFNG, IL2RA, IL6, ICAM1, PTPN22, NOTCH1, HLA-DRB1) and non-coding RNA dysregulation (IFNG-AS1) (PMID: 36420742; PMID: 32916160).

Protective Factors

• Glutamine at HLA-DRbeta1 position 74: Protective against AITD (vs. arginine which confers risk) (PMID: 22735372)
• Moderate alcohol intake: Decreases risk of overt Hashimoto's hypothyroidism (PMID: 24609834)

3. Phenotypes

Clinical Phenotype Spectrum

The following table summarizes the major clinical phenotypes of HE with frequencies, HPO terms, and quality of life impact:

Sources: PMID: 26167010: "Clinical manifestations were cognitive impairment and behavioral changes in 10 (76.9%), sleep disturbance in 9 (69.2%), seizures in 6 (46.1%), headache in 4 (30.8%), psychosis or paranoia in 5 (38.5%), transient symptoms in 6 (46.1%), myoclonus in 4 (30.8%), ataxia or gait disorder in 4 (30.8%)"

Clinical Subtypes

Mattozzi et al. (2020) identified four distinct clinical syndromes (PMID: 31882532): 1. Psychiatric type (29%): Dominated by behavioral and psychiatric manifestations 2. Encephalopathy type (29%): Diffuse cognitive dysfunction and altered consciousness 3. NORSE-like type (25%): New-onset refractory status epilepticus pattern 4. Limbic encephalitis type (17%): Memory impairment and temporal lobe features

Additionally, an ataxia-predominant form has been described with cerebellar dysfunction as the main manifestation (PMID: 36081870), and rare presentations include orthostatic myoclonic jerks (PMID: 35946002), tic disorders (PMID: 24633901), and prominent bilateral tremor (PMID: 27790384).

Nonconvulsive Status Epilepticus

A Korean study of 22 patients found that nonconvulsive status epilepticus (NCSE) on EEG was observed in 6 patients, all of whom were intractable to antiepileptic drugs but responded to immunosuppressants (PMID: 38861245).

4. Genetic/Molecular Information

Causal Genes

No HE-specific causal genes have been identified. HE is not a Mendelian disorder; it follows a polygenic, multifactorial susceptibility model shared with AITD. The inheritance pattern is best described as multifactorial/polygenic with environmental modifiers.

Key Molecular Targets

• ENO1 (alpha-enolase) -- Gene ID: 2023; HGNC: 3350 -- Encodes the NH2-terminal alpha-enolase, target of anti-NAE autoantibodies found in 44% of HE patients. Anti-NAE antibodies show 91% specificity and 50% sensitivity for HE (PMID: 23777101). However, a 2024 systematic review noted that "the proposed anti NH2-terminal-alpha-enolase (anti-NAE) is non-specific for HE" (PMID: 39000209).
• TPO (thyroid peroxidase) -- Gene ID: 7173 -- Target of anti-TPO antibodies, the hallmark serological marker
• TG (thyroglobulin) -- Gene ID: 7038 -- Target of anti-TG antibodies
• HMGB1 (High Mobility Group Box 1) -- Gene ID: 3146 -- Identified as key mediator translating peripheral thyroid autoimmunity into CNS neuroinflammation (PMID: 41782877)

Epigenetic Information

DNA methylation patterns in AITD candidate genes (ITGA6, PRKAA2, DAPK1) differ between patients from regions with different iodine status, "providing a potential mechanism for associations between iodine and AITD" (PMID: 36420742). Non-coding RNA dysregulation, including lncRNA IFNG-AS1, modulates humoral and cellular immune responses in AITD (PMID: 32916160).

5. Environmental Information

Environmental Factors

• Iodine: Excess iodine intake is epidemiologically linked to increased AITD prevalence and alters epigenetic regulation of AITD genes (PMID: 36420742)
• Selenium: Deficiency may promote thyroid autoimmunity; supplementation studies show mixed results (PMID: 24609834)
• Vitamin D: Deficiency reported in AITD patients, but causality unestablished

Lifestyle Factors

Wiersinga (2014) reported: "Moderate alcohol intake decreases the risk on overt GH and overt Hashimoto's hypothyroidism. Current smokers - as well known - are at increased risk for Graves' disease, but - surprisingly - at diminished risk for Hashimoto's thyroiditis" (PMID: 24609834).

Infectious Agents

Infections are postulated to trigger AITD through molecular mimicry, but no specific pathogen has been definitively linked to HE. The gene-environment interaction operates through epigenetic mechanisms (PMID: 21234711).

6. Mechanism / Pathophysiology

Four Competing Mechanistic Hypotheses

The pathogenesis of HE involves four interrelated but distinct hypotheses:

UPSTREAM TRIGGER
      |
      v
Hashimoto's Thyroiditis (genetic susceptibility + environmental triggers)
      |
      v
Systemic Immune Dysregulation (thyroid autoantibodies, T-cell activation)
      |
      +---> Hypothesis 1: AUTOIMMUNE CEREBRAL VASCULITIS
      |     - Perivascular lymphocytic infiltration
      |     - Cerebral hypoperfusion on SPECT
      |     GO: GO:0006954 (inflammatory response)
      |
      +---> Hypothesis 2: ANTI-NEURONAL ANTIBODIES
      |     - Anti-NAE antibodies (44% of cases, 91% specificity)
      |     - Target: alpha-enolase on neuronal surfaces
      |     GO: GO:0002460 (adaptive immune response)
      |
      +---> Hypothesis 3: T-CELL MEDIATED AUTOIMMUNITY
      |     - Brain biopsies: T-cell dominant infiltration
      |     - CD4+ T cells infiltrate brain parenchyma
      |     CL: CL:0000624 (CD4-positive, alpha-beta T cell)
      |
      +---> Hypothesis 4: BBB DYSFUNCTION + HMGB1 (MOST RECENT)
    - CSF protein elevation (88.8%)
    - CSF anti-TPO presence
    - CSF IL-6 elevation
    - HMGB1 cytoplasmic translocation
    GO: GO:0045087 (innate immune response)
      |
      v
DOWNSTREAM EFFECTS
- Microglial activation (CL:0000129)
- A1-type neurotoxic astrocyte polarization (CL:0000127)
- Disrupted AQP4 polarization
- Neuronal dysfunction --> cognitive/psychiatric/seizure symptoms

The HMGB1 Breakthrough (2026)

Wang et al. (2026) provided the most mechanistically complete model to date using C57BL/6 mice with experimental autoimmune thyroiditis (EAT). Key findings include:

• "Mice with EAT, despite preserved systemic thyroid hormone levels, displayed significant deficits in both spatial and recognition memory" (PMID: 41782877)
• Pronounced microglial activation in cortex and hippocampus
• Increased A1-like neurotoxic astrocytes
• Disrupted AQP4 (aquaporin-4) polarization
• Infiltrating CD4+ T cells in brain parenchyma
• "Our results identify Hmgb1 as a key factor that translates peripheral thyroid autoimmunity into central neuroinflammation. It functions as a driving force behind pathogenic glial" activation (PMID: 41782877)

Molecular Pathways

• NF-kappaB pathway: HMGB1 activates NF-kappaB signaling in microglia and astrocytes (GO: GO:0007249)
• TLR4/RAGE signaling: HMGB1 binds TLR4 and RAGE receptors to initiate neuroinflammation
• Complement cascade: Potential role in vasculitic-type HE
• Cytokine signaling: CSF IL-6 elevation documented (PMID: 38085696)

Immune System Involvement

Relevant GO Terms

• GO:0006954 -- Inflammatory response
• GO:0006955 -- Immune response
• GO:0045087 -- Innate immune response
• GO:0002460 -- Adaptive immune response
• GO:0050776 -- Regulation of immune response
• GO:0019882 -- Antigen processing and presentation

7. Anatomical Structures Affected

Organ Level

Brain Regions

• Cerebral cortex (UBERON:0000956): Diffuse cortical dysfunction
• Hippocampus (UBERON:0002421): Memory impairment; microglial activation in mouse model
• Cerebellum (UBERON:0002037): Ataxia-predominant forms
• Temporal lobe (UBERON:0001871): Most frequent focal abnormality on MRI
• Basal ganglia/thalamus (UBERON:0002420 / UBERON:0004703): Movement disorders
• White matter (UBERON:0002316): T2/FLAIR hyperintensities

Cell Types Affected

• Neurons (CL:0000540): Primary target of immune attack
• Microglia (CL:0000129): Activated in neuroinflammation
• Astrocytes (CL:0000127): A1 neurotoxic polarization
• CD4+ T lymphocytes (CL:0000624): Brain-infiltrating effectors
• Thyroid follicular cells (CL:0002257): Primary autoimmune target
• Cerebral vascular endothelium (CL:0002543): BBB dysfunction

Lateralization

Brain involvement is typically bilateral and diffuse, though focal presentations occur. MRI lesions when present are often asymmetric. Anti-NAE-positive patients may show fluctuating white matter lesions (PMID: 31525528).

8. Temporal Development

Onset

• Age distribution: Bimodal, with peaks at 20-30 years and 50-70 years (PMID: 19363998). Range: 8 to 87+ years. Median onset ~48.5 years in some cohorts (PMID: 26167010).
• Onset pattern: Typically acute or subacute (days to weeks)
• Thyroid status at onset: Most patients are euthyroid; only 20% had prior history of Hashimoto's thyroiditis (PMID: 19363998)

Disease Course

Two main clinical course patterns: 1. Acute/relapsing vasculitic type: Stroke-like episodes, seizures, focal neurological deficits; episodic with remissions and relapses 2. Diffuse progressive type: Insidious cognitive decline resembling dementia, altered consciousness, psychosis; progressive course

Prognosis

• Glucocorticoid effectiveness: 60.94% (PMID: 39000209)
• Relapse rate: 31.67% following treatment (PMID: 39000209)
• Older adults (65+): 56.8% return to near-baseline; 29.4% partial improvement (PMID: 40323355)
• Overall with immunosuppressants: 90.5% (19/21) showed good outcomes (PMID: 38861245)
• Complete steroid response: Only 31.6% (6/19) (PMID: 31882532)
• Mortality: Generally considered non-fatal with appropriate treatment, though data are limited

9. Inheritance and Population

Epidemiology

• Prevalence: Estimated 2.1 per 100,000 (based on extrapolation from Hashimoto's thyroiditis prevalence and estimated HE occurrence rate)
• Incidence: Not precisely established; very rare
• Sex ratio: Female predominance, F:M ratio approximately 4:1 to 5:1; in the 84-patient Japanese series, 58 women and 26 men (F:M ~2.2:1) (PMID: 19363998)

Genetic Architecture

• Inheritance pattern: Multifactorial/polygenic (not Mendelian)
• Heritability: ~70% for underlying AITD (twin studies)
• Penetrance: Very low -- millions have AITD but only a tiny fraction develop HE
• Expressivity: Highly variable (psychiatric, encephalopathic, NORSE-like, limbic)

Population Demographics

• Geographic distribution: Reported worldwide; largest case series from Japan and Europe
• Ethnic predisposition: No clear ethnic predilection, though AITD prevalence varies by population
• Age distribution: Bimodal (20-30 and 50-70 years); can occur from childhood to elderly

10. Diagnostics

Diagnostic Criteria

HE remains a diagnosis of exclusion. The most rigorous proposed criteria (Mattozzi et al. 2020) require:

1. Subacute cognitive impairment, psychiatric symptoms, or seizures
2. Euthyroid or mild hypothyroidism
3. Serum TPOAb >200 IU/mL
4. Absent neuronal surface antibodies
5. No other identifiable etiologies

Critical limitation: The frequency of TPOAb in patients with possible autoimmune encephalitis without neuronal antibodies (8.1%) was similar to that of controls (8.2%), revealing poor diagnostic specificity (PMID: 31882532).

Laboratory Tests

Neuroimaging

• Brain MRI: Normal in 70-85% of cases. When abnormal: non-specific white matter T2/FLAIR hyperintensities (PMID: 36809420). In anti-NAE positive patients, "expanding and diminishing white matter lesions, emerging subcortical high-intensity spots on diffusion-weighted images, or reversible limbic lesions, which worsened at relapse and improved after recovery following immunotherapies" (PMID: 31525528).
• SPECT: Decreased cerebral blood flow (supports vasculitic hypothesis)
• FDG-PET: May show cortical hypometabolism

Electrophysiology

• EEG abnormalities: Present in 53.8-80% of cases
• Most common: generalized slowing
• NCSE observed in 6/22 patients in one series (PMID: 38861245)

Differential Diagnosis

Genetic Testing

Genetic testing is not applicable for HE diagnosis. HLA typing for AITD susceptibility is a research tool, not clinically indicated.

11. Outcome/Prognosis

Treatment Response and Outcomes

Prognostic Factors

• Early treatment initiation: Associated with better outcomes
• NCSE on EEG: Poor prognostic indicator; intractable to AEDs (PMID: 38861245)
• Age: Older patients may have slower recovery but still respond
• Anti-NAE positivity: Tends to be associated with acute encephalopathy pattern

Complications

• Residual cognitive deficits
• Persistent seizure disorder
• Steroid-related adverse effects (with prolonged therapy)
• Relapse upon steroid tapering

12. Treatment

Treatment Algorithm

FIRST-LINE: IV Methylprednisolone
  1g/day x 3-5 days (MAXO:0000750, CHEBI:6888)
  OR 500mg/day with similar outcomes
  --> Oral prednisolone taper
      |
      | If inadequate response or relapse
      v
SECOND-LINE OPTIONS:
  - IVIG 0.4g/kg/day x 5 days (MAXO:0000376)
  - Plasmapheresis (MAXO:0000127)
      |
      | If still refractory
      v
THIRD-LINE:
  - Rituximab (CHEBI:64357) - B-cell depletion
  - Azathioprine (CHEBI:2948)
  - Mycophenolate mofetil (CHEBI:168396)
      |
      | Novel/Emerging
      v
NOVEL THERAPIES:
  - Efgartigimod-alpha (FcRn antagonist) - rapid improvement
    in steroid-intolerant patients

Pharmacotherapy Details

First-line -- Corticosteroids (MAXO:0000750): - IV methylprednisolone 1g/day for minimum 3 days: used in 37.2% of older patients - Reduced dose 500mg/day (9.8%) with similar outcomes - "Majority of older patients (n = 48, 94.1%) were initially treated with steroids... Response is favorable, with 56.8% (n = 29) returning to near baseline functional status, while 29.4% (n = 15) showed partial improvement" (PMID: 40323355)

Second-line -- IVIG (MAXO:0000376): - "In the majority of the selected case-reports, IVIG was associated with a good outcome, sometimes even with dramatic improvements" (PMID: 37745658)

Novel -- FcRn antagonist (efgartigimod-alpha): - 800mg dose in an 83-year-old steroid-intolerant patient with recurrent HE - First report of this therapeutic class for HE (PMID: 41731401)

Supportive Care

• Antiepileptic drugs (MAXO:0000756): For seizure management (note: NCSE may be refractory to AEDs)
• Levothyroxine (CHEBI:18332, MAXO:0000779): For hypothyroidism when present
• Rehabilitation (MAXO:0000011): Cognitive re-education, physical therapy, psychosocial support -- "Evidence regarding rehabilitation for people affected by HE is limited, but neurorehabilitation strategies adapted from other neurological conditions... may be beneficial" (PMID: 40149702)

13. Prevention

Primary Prevention

No established primary prevention exists for HE. General strategies to reduce AITD risk include: - Adequate but not excessive iodine intake - Selenium supplementation (evidence inconclusive) - Vitamin D sufficiency maintenance - Avoidance of environmental triggers in genetically susceptible individuals

Secondary Prevention (Early Detection)

• Screening for anti-TPO/anti-TG antibodies in patients with unexplained encephalopathy
• Low threshold for HE evaluation in patients with known Hashimoto's thyroiditis presenting with neuropsychiatric symptoms
• EEG and MRI in patients with AITD and cognitive decline

Tertiary Prevention

• Maintenance immunosuppression to prevent relapse (31.67% relapse rate)
• Long-term steroid taper monitoring
• Regular neurological follow-up
• Seizure prophylaxis when indicated

Genetic Counseling

Not typically indicated for HE specifically, though family members may be screened for AITD given the strong heritability (~70%).

14. Other Species / Natural Disease

Animal Models of Thyroid Autoimmunity

OS Chicken Model

The OS chicken is the classic animal model for Hashimoto's thyroiditis. IL-15 was identified as constitutively upregulated: "Only IL-15 was up-regulated at all time points. IL-15 was also shown to be up-regulated in spleens of OS birds at embryonic day 20 and 5 days posthatch" (PMID: 11937583). Genetic analysis suggests SAT is regulated by a maximum of 3 genes (PMID: 11862410).

Comparative Biology

No animal model fully recapitulates the complete HE phenotype (thyroid autoimmunity + CNS dysfunction + steroid responsiveness). The EAT mouse model comes closest by demonstrating that thyroid autoimmunity alone -- in a euthyroid state -- can produce cognitive deficits and neuroinflammation.

15. Model Organisms

Available Models

1. OS Chicken (Gallus gallus) - Type: Spontaneous, avian - Phenotype recapitulation: Excellent for Hashimoto's thyroiditis (lymphocytic thyroid infiltration, autoantibodies, hypothyroidism) - CNS phenotype: None documented - Genetic regulation: Maximum 3 genes; one recessive gene for thyroid susceptibility, 1-2 dominant genes for immune abnormality - Resources: Available through specialized poultry genetics laboratories

2. C57BL/6 EAT Mouse (Mus musculus) - Type: Induced (porcine thyroglobulin injection + CFA) - Phenotype recapitulation: Best available model for HE -- cognitive deficits in spatial and recognition memory despite euthyroid state - Key features: Microglial activation, A1 astrocyte polarization, disrupted AQP4, HMGB1 translocation, CD4+ T cell brain infiltration - Limitations: Induced rather than spontaneous; single genetic background; acute model - Resources: Standard laboratory mouse; induction protocol described in PMID: 41782877

3. Canine Lymphocytic Thyroiditis - Type: Naturally occurring - Breeds affected: Multiple (Beagle, Doberman Pinscher, Golden Retriever, others) - Phenotype: Thyroid autoimmunity without encephalopathy - Relevance: Comparative pathology of thyroid autoimmunity only

Evidence Base

Key Publications Supporting This Report

Limitations and Knowledge Gaps

1. Diagnostic uncertainty: HE remains a diagnosis of exclusion with no pathognomonic biomarker. Anti-TPO antibodies lack specificity, and anti-NAE antibodies are present in fewer than half of cases with contested specificity.

2. No randomized controlled trials: All treatment evidence derives from case reports, case series, and retrospective studies. No RCTs exist for any HE therapy.

3. Pathogenic mechanism unknown: While four hypotheses exist and the HMGB1 mouse model is promising, the exact mechanism by which thyroid autoimmunity causes CNS dysfunction in humans remains unresolved. The mouse model findings await human validation.

4. Heterogeneity: The four clinical subtypes may represent distinct diseases grouped together by the presence of thyroid antibodies, which may be an epiphenomenon rather than a disease marker.

5. Epidemiological data: Prevalence and incidence figures are estimates. No population-based epidemiological studies exist for HE.

6. Long-term outcomes: Limited longitudinal data on cognitive recovery, relapse patterns, and quality of life over years.

7. Pediatric HE: Very limited data in children; most studies focus on adults.

8. No HE-specific genetic studies: All genetic data are extrapolated from AITD studies. No GWAS or exome studies have been performed specifically for HE.

9. Animal model limitations: No single model recapitulates the full HE triad (thyroid autoimmunity + CNS dysfunction + steroid responsiveness).

Proposed Follow-up Experiments/Actions

High Priority

1. Human validation of HMGB1: Measure CSF HMGB1 levels in HE patients vs. Hashimoto's thyroiditis patients without encephalopathy vs. healthy controls to validate the mouse model finding.

2. Prospective diagnostic cohort study: Evaluate a panel of biomarkers (anti-NAE, CSF IL-6, HMGB1, anti-TPO, CSF protein) in a prospective cohort of patients with suspected autoimmune encephalitis to derive an evidence-based diagnostic algorithm.

3. Randomized controlled trial of immunotherapy: Compare steroid monotherapy vs. steroid + IVIG vs. early rituximab in newly diagnosed HE using validated outcome measures (CASE score, mRS).

Medium Priority

1. Single-cell RNA-seq of brain biopsy/autopsy tissue: Characterize the cellular landscape of HE-affected brain tissue to identify the dominant immune cell populations and their activation states.

2. GWAS of HE patients: Perform genome-wide association study in HE (distinct from general AITD) to identify HE-specific susceptibility loci that may distinguish HE from uncomplicated Hashimoto's thyroiditis.

3. HMGB1 inhibitor therapeutic trial: Based on the mouse model, test HMGB1 inhibitors (e.g., glycyrrhizin, anti-HMGB1 antibodies) as targeted therapy in HE.

4. Longitudinal neuroimaging study: Track brain structural and functional changes (MRI, PET, SPECT) before and after treatment to identify imaging biomarkers of treatment response.

Lower Priority

1. EAT mouse model refinement: Develop a chronic/relapsing EAT model that better recapitulates the relapsing-remitting course of HE, including steroid responsiveness testing.

2. International HE registry: Establish a multicenter registry to collect standardized clinical, serological, imaging, and outcome data from HE patients worldwide.

3. Quality of life study: Administer validated QoL instruments (EQ-5D, SF-36) to HE patients at diagnosis and during follow-up to quantify the disease burden and recovery trajectory.

Ontology Term Summary

Disease Ontology

• MONDO:0015537 -- Hashimoto encephalopathy

Phenotype Terms (HPO)

• HP:0100543 -- Cognitive impairment
• HP:0001250 -- Seizures
• HP:0000709 -- Psychosis
• HP:0001336 -- Myoclonus
• HP:0001251 -- Cerebellar ataxia
• HP:0002360 -- Sleep disturbance
• HP:0002315 -- Headache
• HP:0001337 -- Tremor
• HP:0007185 -- Loss of consciousness
• HP:0002922 -- Increased CSF protein
• HP:0002353 -- EEG abnormality

Cell Types (CL)

• CL:0000540 -- Neuron
• CL:0000129 -- Microglial cell
• CL:0000127 -- Astrocyte
• CL:0000624 -- CD4-positive, alpha-beta T cell
• CL:0002257 -- Thyroid follicular cell

Anatomical Structures (UBERON)

• UBERON:0000955 -- Brain
• UBERON:0002421 -- Hippocampus
• UBERON:0000956 -- Cerebral cortex
• UBERON:0002037 -- Cerebellum
• UBERON:0002046 -- Thyroid gland
• UBERON:0002316 -- White matter

Biological Processes (GO)

• GO:0006954 -- Inflammatory response
• GO:0006955 -- Immune response
• GO:0045087 -- Innate immune response
• GO:0019882 -- Antigen processing and presentation

Chemical Entities (CHEBI)

• CHEBI:6888 -- Methylprednisolone
• CHEBI:64357 -- Rituximab
• CHEBI:2948 -- Azathioprine
• CHEBI:18332 -- Levothyroxine

Medical Actions (MAXO)

• MAXO:0000750 -- Corticosteroid therapy
• MAXO:0000376 -- Intravenous immunoglobulin therapy
• MAXO:0000127 -- Plasmapheresis
• MAXO:0000756 -- Antiepileptic drug therapy
• MAXO:0000779 -- Thyroid hormone replacement
• MAXO:0000011 -- Rehabilitation therapy

Report generated from systematic investigation across 5 iterations, reviewing 105 papers and confirming 13 findings. Disease characterization spans all 15 required sections with full ontology mapping and 22+ cited publications.